The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both.

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Medscape Medical News, March 31, 2025 ACC 2025 Oral GLP-1 Receptor Agonist Reduces CV Risk Oral semaglutide ... enhance the early detection of chronic kidney disease in low-risk patients, a ...

Semaglutide increased maximum walking distance ... end-stage kidney disease and cardiovascular death in adults with T2D and chronic kidney disease.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

You should inject Ozempic (semaglutide) into your stomach ... kidney disease and fatal heart problems if you have chronic kidney disease and type 2 diabetes Doctors prescribe Ozempic along ...

Share on Pinterest Semaglutide may be effective ... excluded participants who had other chronic liver problems besides nonalcoholic fatty liver disease. Other exclusion criteria included ...